Recent Updates
Recently added Catalysts
ALGS Neutral Sentiment

Association of Baseline Characteristics and Plasma ALG-001075 to HBsAg Responses in HBeAg+ CHB subjects following ALG-000184±ETV treatment

Key Takeaway: The article discusses the association of baseline characteristics and plasma ALG-001075 levels with HBsAg responses in HBeAg+ chronic hepatitis B subjects after treatment with ALG-000184±ETV. It provides insights into the clinical trial aspects but lacks specific results or conclusions.
Price reaction · baseline $14.75 (2024-05-31 close) · 3 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
+4.5%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR
Last updated: Jun 1, 2024